1910 Genetics, Inc.

Based in Massachusetts, US, and established in 2018, 1910 Genetics operates as a biotechnology research organization. The biotech organization is founded by Jen Nwankwo (CEO). In September 2021, 1910 Genetics, Inc. raised USD 550,000 in grant funding from a new investor National Institute of Neurological Disorders and Stroke.

1910 Genetics first develops an understanding of the molecular basis of the disease, this works as the north star for the research and drives the integration of artificial intelligence computation and biological automation to accelerate the design of small molecule and protein therapeutics. The two discovery engines used by the organization are ELVIS™ and ROSALYND™. ELVIS™ includes SUEDE™ which is a screening technology, BAGEL™ which picks pharmacological features from the database and is input by experienced medical chemists, CANDID™ includes a graph neural network that excels at QSAR tasks and provides a platform for virtual screening and lead optimization. Similarly, ROSALYND™ also includes EMBARR™, AETHON™, and PEGASUS™.

Its product is a multi-module drug discovery platform that uses machine learning to generate more novel drug candidates and help companies with their pharmaceutical research and development. The company plans to use the 2021 funding to support the discovery of a novel small molecule drug for the treatment of chronic pain. As of 2022, the organization is applying its technology to drug discovery programs in neuroscience, infectious disease, immunology, and oncology.